WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 205782
Description: ME -143 is a derivative of triphendiol and is a highly potent, pan acting ant-cancer. It is active against every melanoma cell line tested to date and is able to sensitize melanoma cell lines to the standard of care drug, dacarbazine, and members of the platinum drug scaffold. Proof of concept studies in animal models of melanoma have demonstrated that orally delivered ME-143 retards tumour proliferation. The ME-143 mechanism of action in melanoma has not been fully elucidated. ME-143 is non-clastogenic.
MedKoo Cat#: 205782
Chemical Formula: C21H18O4
Exact Mass: 334.12051
Molecular Weight: 334.36522
Elemental Analysis: C, 75.43; H, 5.43; O, 19.14
ME-143 is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to firstname.lastname@example.org to inquire quote.
Synonym: NV143; ME143; ME-143; ME 143.
IUPAC/Chemical Name: 4,4'-(7-hydroxychroman-3,4-diyl)diphenol
InChi Key: VXHSDGZMRLGSEJ-UHFFFAOYSA-N
InChi Code: InChI=1S/C21H18O4/c22-15-5-1-13(2-6-15)19-12-25-20-11-17(24)9-10-18(20)21(19)14-3-7-16(23)8-4-14/h1-11,19,21-24H,12H2
SMILES Code: OC1=CC2=C(C=C1)C(C3=CC=C(O)C=C3)C(C4=CC=C(O)C=C4)CO2
The following data is based on the product molecular weight 334.36522 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
ME-143 is the lead oncology drug candidate from Marshall Edwards. In pre-clinical studies, ME-143 has demonstrated potent activity against a number of tumor cell lines, including breast, colorectal and ovarian. In addition to broad single-agent activity, ME-143 has also shown an ability to enhance the cytotoxic effects of chemotherapy in pre-clinical studies. Marshall Edwards owns exclusive worldwide rights to ME-143.